---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-118586"
form_type: "8-K"
ticker: "LRMR"
cik: "0001374690"
company_name: "Larimar Therapeutics, Inc."
filed_at: "2024-10-30T23:59:59+00:00"
generated_at: "2026-05-30T08:08:25.019767+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Larimar reports Q3 2024 net loss of $15.5M; cash $203.7M, BLA target 2H 2025

## Summary
- Net loss of $15.5M ($0.24 per share) vs $9.1M loss ($0.21 per share) in Q3 2023.
- Cash, cash equivalents and marketable securities $203.7M as of Sep 30, 2024; projected runway into 2026.
- Nomlabofusp program update in mid-Dec with safety, PK, frataxin data from 25 mg daily OLE study.
- PK run-in study in adolescents on track by year-end 2024; global confirmatory study planned mid-2025.
- BLA submission for nomlabofusp targeted for 2H 2025 to support potential accelerated approval.

## SEC filing metadata
- accession: 0000950170-24-118586
- form_type: 8-K
- ticker: LRMR
- cik: 0001374690
- company_name: Larimar Therapeutics, Inc.
- filed_at: 2024-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374690/000095017024118586/0000950170-24-118586-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374690/000095017024118586/lrmr-20241030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-118586
- JSON: https://secwatch.observer/filing/0000950170-24-118586.json
- Plain text: https://secwatch.observer/filing/0000950170-24-118586.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.